GLP-1s Are Changing Cardiovascular Risk

Most obesity care programs are measuring weight loss. That is not the same as measuring cardiovascular risk reduction, and treating them as the same thing is quietly undermining what GLP-1 programs are actually capable of delivering.

The medications have outpaced the measurement frameworks built around them. Patients are losing significant weight, but the metrics most programs report were designed for a different era of obesity care, one where weight loss was the end goal rather than the starting point.

What the Research Is Actually Saying


Research comparing tirzepatide and semaglutide found projected reductions in 10-year cardiovascular disease risk across both agents. This is significant because approximately two-thirds of obesity-related mortality is attributable to cardiovascular disease, not obesity itself.

GLP-1 programs may be producing cardiovascular benefits that their own reporting infrastructure is not designed to detect or document.

What Data Gets Missed


Blood pressure is a more direct signal of cardiovascular risk than weight. When a GLP-1 program produces notable weight loss, blood pressure should move. But whether it does, by how much, and how quickly depends on individual physiology, medication interactions, and behavioral factors that a monthly clinic visit cannot reliably capture. In-office readings also miss variability entirely, for example a patient who presents at 128/82 may have a different pattern at home across different times of day and activity levels.

Body composition is the other gap, and visceral fat specifically is the one most programs are not measuring. Unlike subcutaneous fat, visceral fat is metabolically active. It releases inflammatory compounds that drive insulin resistance and accelerate atherosclerosis, contributing directly to cardiovascular risk independent of total body weight. Despite this, a Nature Reviews Endocrinology consensus statement found that visceral fat assessment is not routinely obtained in clinical practice, even in patients with obesity. Two patients can achieve identical weight loss on GLP-1 therapy and arrive at very different cardiovascular risk profiles depending on how much visceral fat was actually lost. A program reporting aggregate weight loss without that data is describing an outcome it has not actually measured.

The Program Design Problem


The disconnect between what GLP-1 medications can accomplish and what programs are built to document is not a clinical problem. Programs that track only weight are not positioned to demonstrate cardiovascular outcomes to payers, health systems, or value-based care partners, even if those outcomes are occurring.

For employer-sponsored obesity programs, this has a direct impact on how they compete. Employers evaluating programs are increasingly distinguishing between services that primarily manage medication access and those that deliver a clinically-backed care model. A program that monitors blood pressure trends, visceral fat reduction, and cardiovascular risk alongside weight loss is making a different case for its clinical value, and that distinction matters when an employer is deciding what to offer their workforce.

Programs that can track what is actually happening across their patient population over time, not just average weight loss but blood pressure improvement, body composition change, and sustained metabolic progress, are the ones that can demonstrate growth and clinical credibility to existing and prospective partners. Continuous at-home monitoring is what makes that level of reporting possible.

Blood pressure variability and body composition are the two signals most likely to reveal whether cardiovascular risk is actually moving between clinic visits. Capturing them continuously, at home, without adding burden to care teams or patients, is what closes the gap between the outcomes GLP-1 programs are producing and the evidence base they are building. For a closer look at what that monitoring infrastructure looks like in practice, see Heart Health in the GLP-1 Era: The Role of Remote Patient Monitoring.

References

Mamas MA, Bays H, Li R, et al. Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. European Heart Journal Open. 2025. Available via PMC.

Després JP, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nature Reviews Endocrinology. 2020. Available via PMC.